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Abstract
Background: To investigate the effect of low-level laser therapy to salivary gland function in diabetic patients with
hyposalivation. Methods: Twelve diabetic patients were recruited. A 940-nm indium-gallium-arsenide-phosphide lowpower semiconductor diode laser was used to stimulate the major salivary glands with an irradiation time of 40 s; this
was done three times a week for 2 consecutive weeks. Patients were given questionnaires related to dry mouth
symptoms. Salivary flow rates, questionnaire responses as well as MUC7, MUC5B and histatin 5 protein salivary
concentrations were assessed at the first and sixth visits after laser therapy as well at the 6-week follow-up visit.
Results: The unstimulated salivary flow rate and MUC5B concentration at the follow-up visit significantly increased (p
< 0.01). Histatin 5 concentration significantly decreased at the follow-up visit compared with that at the first visit (p <
0.05). The mean dry mouth score revealed a significant decrease in dry mouth symptoms at the sixth visit and follow-up
visit compared with those at the first visit (p < 0.001). The positive correlation between dry mouth score and flow rate
was the strongest at the sixth visit (rs = 0.549). Conclusions: Low-level laser therapy increased the salivary flow rate
and decreased dry mouth symptoms in diabetic patients.
Keywords: diabetes, hyposalivation, laser therapy, salivary proteins

tissues from the outer environment and to hydrate and
lubricate the oral cavity. Furthermore, mucins aid in
mastication, speech and swallowing and are involved in
agglutinating oral microorganisms.1,2 There are two
mucin isoforms based on molecular weight (MW): highMW (>1000 kDa) gel-forming MUC5B and low-MW
(120–150 kDa) MUC7.5 MUC5B lubricates oral surfaces
due to its hydrophilic carbohydrate properties. MUC7
has a shorter oligosaccharide side chain than MUC5B;
however, MUC5B binds to fewer oral microorganisms
than MUC7.2

Introduction
Saliva is composed of approximately 99% water; the
remaining 1% consists of electrolytes and several types
of macromolecules, including antimicrobial factors.1,2
Approximately 65% of unstimulated whole saliva
comes from the submandibular glands, 20% from the
parotid glands, 7%–8% from the sublingual glands and
5%–8% from the minor salivary glands. However, when
stimulated, saliva from the parotid glands increases to
approximately 50% of the whole saliva volume and the
remaining 50% comes from the other salivary glands as
well as the gingival crevicular fluid.1,2 Saliva has several
functions, which include lubricating the oral cavity and
protecting against pathogens with defensive proteins
such as mucins and histatins.1-3

Histatins are histidine-rich antimicrobial peptides
produced from all major salivary glands and are known
for their antifungal activity.6 A study revealed that
histatin 5, a histatin subtype, has remarkable fungicidal
and fungistatic activities against Candida albicans.5
Salivary gland hypofunction includes subjective symptoms
and objective signs of dry mouth that, in most cases, are
related to systemic diseases, such as Sjögren’s syndrome,

Mucins are salivary glycoproteins that are mostly
secreted by the submandibular glands.3,4 The function of
mucin in the salivary defence system is to protect oral
14
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hypertension and diabetes mellitus.7 Some studies have
reported an association between diabetes mellitus and
hyposalivation. Type 1 and 2 diabetic patients show a
high prevalence of dry mouth.8,9
A study has demonstrated that the MUC5B concentration
tends to decrease in patients showing hyposalivation.10
However, another study found that MUC5B and MUC7
concentrations were not significantly different between
Sjögren’s syndrome patients with oral dryness and
controls.7 Moreover, a decrease in histatin 5 concentration
was related to an increased susceptibility to fungal
infection.11 Thus, we speculated that mucin and histatin
5 concentrations are decreased in diabetic patients with
hyposalivation.
Dry mouth symptoms can be relieved by modifying
eating/drinking habits and using salivary substitutes,
lubricants or sialogogues to stimulate salivary flow;2
however, the lubricating effect lasts for only as long as
these agents are used.
A recent study demonstrated that low-level laser therapy
(LLLT) or biostimulation increased the salivary flow
rate.12 LLLT involves the noninvasive and safe clinical
application of light at a power ranging from 50 mW to
500 mW and wavelength ranging from 630 nm to 980
nm.13 LLLT significantly increases the salivary flow rate
in xerostomia patients12,14 and has been demonstrated to
be an effective noninvasive treatment in patients with
mouth dryness.15 To the best of our knowledge, the
effect of LLLT on the major salivary glands of diabetic
patients with hyposalivation has not been reported. We
hypothesised that use of LLLT on the major salivary
glands would improve the salivary flow rate, and we
evaluated the quality of saliva by measuring MUC7,
MUC5B and histatin 5 levels in diabetic patients with
hyposalivation.

Methods
Participant recruitment. The study protocol was
approved by the Ethics Committee of Bangkok Hospital,
Bangkok, Thailand, in accordance with the ethical
standards of the Declaration of Helsinki.
Twelve diabetic patients who visited the diabetic clinic
at Bangkok Hospital from November 2015 to April
2016 were recruited on a voluntary basis. The diabetic
patients were diagnosed by a physician according to one
of the following four criteria: 1) HbA1C level of ≥ 6.5%,
2) fasting plasma glucose level of ≥126 mg/dL (7.0
mmol/L; fasting was defined as no caloric intake for at
least 8 h), 3) 2-h plasma glucose level of ≥200 mg/dL
(11.1 mmol/L) during an oral glucose tolerance test and
4) random plasma glucose level of ≥200 mg/dl (11.1
mmol/L).16 The estimated sample size was 10 participants.
Makara J. Health Res.

Alpha was set to 0.05, power to 90%, with standard
deviation referred to form our pilot study (0.14), and
expected difference after LLLT. As our inclusion
criteria is USFR less than 0.25 mL/min and mean of
adult USFR is 0.40 mL/min.
The patients were initially approached by giving them
an educational brochure on diabetes-related oral health
issues. Only patients diagnosed with hyposalivation, an
unstimulated salivary flow rate (USFR) of <0.25
mL/min, were recruited. The following patients were
excluded: those aged <18 years, those who were
pregnant, those diagnosed with oral or maxillofacial
neoplasms, those who consumed >1 drink per day
(women) or 2 drinks per day (men)17 and those who
used illicit drugs (long-term regular injection of opioids,
amphetamines or cocaine).18 A brief medical history of
each patient was taken as supporting information.
Low-level laser therapy (LLLT). Each patient
underwent an oral examination prior to laser therapy.
Laser therapy was performed by a dentist at Bangkok
Hospital, during which the parotid and submandibular
glands were extraorally exposed and the sublingual
glands were intraorally exposed. Slow circulating laser
movements were performed during therapy to ensure
comprehensive treatment of the gland area. The salivary
glands were stimulated with a 940-nm indium-galliumarsenide-phosphide low-power semiconductor diode
laser (EpicTM10, Biolase Inc, Irvine, CA, USA).
Stimulation was performed three times a week for 2
consecutive weeks. The dentist and patients wore
protective eyeglasses during the procedure. Each
parotid, submandibular and sublingual gland was
stimulated using 0.1 W output power for 40 s/cm2 area.
An energy density (ED) of 4 J/cm2 was used based on
previous studies12,14,15,19,20 along with the following
equation: ED (J/cm2) = W × s/cm2.
Salivary flow rate measurement. Saliva was collected
three times at the first visit prior to laser therapy, at the
sixth visit after laser therapy and at the 6-week followup visit. Unstimulated and stimulated whole saliva
collection was performed from nine in the morning to
noon using standard techniques as described by
Navazesh and Christensen.21 Prior to saliva collection, the
patients were instructed to stop eating, drinking and
smoking for 1 h. For unstimulated saliva collection, the
patients were directed to lean forwards and spit their
saliva for 5 min into a sterilised plastic cup that was preweighed using a digital scale (Denver Instrument
Balance, Bohemia, NY, USA). The collection procedure
was repeated two more times. The USFR was calculated
using the mean weight of the three saliva samples
divided by 5 mins.
To stimulate saliva flow, the patients were instructed to
chew 1 g of tasteless paraffin (Parafilm, Neenah, WI,
April 2018 | Vol. 22 | No. 1
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USA) and to not swallow their saliva during chewing.
Those with dentures were directed to chew the paraffin
without removing their dentures. All patients were told
to spit their saliva into a pre-weighed plastic cup every
30 s for 2 mins. The collection procedure was repeated
two more times. The stimulated salivary flow rate
(SSFR) was calculated using the mean weight of the
three saliva samples divided by 2 min.
Enzyme-linked immunosorbent assay (ELISA) (MyBioSource, San Diego, CA, USA) was performed to determine
MUC7, MUC5B, and histatin 5 salivary protein levels.
Unstimulated saliva was used for mucin analysis as
mucins are mostly produced from the submandibular
and sublingual glands,4 whereas stimulated saliva was
used for histatin 5 analysis because the parotid glands,
where histatin 5 is produced, are more involved in
stimulated saliva secretion.9 ELISA was performed in
triplicate following the manufacturer’s instructions.
Dry mouth symptoms. A questionnaire related to
xerostomia was given to each patient three times: at the
first visit before laser therapy, at the sixth visit after
laser therapy, and at the 6-week follow-up visit.
Because dry mouth symptoms are subjective, a selfadministered questionnaire was used to assess
xerostomia symptoms. The 11-item questionnaire, as
modified from the Xerostomia Inventory-Dutch
Version22, is shown in Table 1. A visual analogue scale
was used to quantify the response of each item [not
agree (0) to totally agree (10)]. The mean dry mouth
score and the correlation between dry mouth score and
salivary flow rate were analysed for each visit.
Statistical analysis. Statistical analysis was performed
using SPSS Statistics for Windows, version 22 (IBM
Corp, Armonk, NY, USA). Statistical analysis was
performed using non-parametric tests because the data
were not normally distributed. Salivary flow rate,
salivary protein concentrations and dry mouth score for
each item were assessed using the Friedman test
followed by the post hoc Wilcoxon signed-rank test to
determine significant differences. Mean salivary flow
No.
1
2
3
4
5
6
7
8
9
10
11

Table 1. Questionnaire Items
Question
I sip liquids to aid in swallowing food (SIP-LIQ)
My mouth feels dry when eating a meal (DRY-MEL)
I get up at night to drink (NGT-DRK)
My mouth feels dry (MTH-DRY)
I have difficulty eating dry foods (DIF-DRY)
I suck sweets or cough lozenges to relieve dry mouth
(SWT-DRY)
My lips feel dry (LIP-DRY)
I have a lot of dental caries (DEN-CAR)
I have bad breath (BAD-BRH)
My tongue sticks to my palate (TNG-PLT)
I have bleeding when brushing (BLD-BRS)
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rates, salivary protein concentrations and dry mouth
scores were presented in tables. Correlation between
mean dry mouth score and salivary flow rate during the
different visits were analysed using Spearman rank test.
Dry mouth scores were reversed prior to analysis (i.e., 8
became 2). Mean dry mouth scores per visit and
correlation between mean dry mouth scores and salivary
flow rate during the different visits were presented in
tables. A p-value of <0.05 was considered significant.

Results
Twelve diabetic patients (6 males and 6 females aged
37–86 years) were recruited. All patients participated
until the sixth visit, and 10 patients returned for the 6week follow-up visit.
Unstimulated Salivary flow rates (USFR). A trend of
increased USFR was demonstrated over the study
period (Table 2). There were significant increases in the
USFR between the first and sixth visits (p = 0.005) and
between the first visit and the 6-week follow-up visit (p
= 0.005). No significant difference was found between
the sixth visit and the 6-week follow-up visit (p =
0.241).
Stimulated Salivary Flow Rates (SSFR). The results
exhibited a trend of increased SSFR over the course of
the study (Table 2); however, there were no significant
differences during the visits at the three different times
(p > 0.05).
Salivary Proteins. MUC7, We found a trend of
decreased MUC7 concentration over the course of the
study (Table 2) Although slight decreases were noticed
at the sixth visit and the 6-week follow-up visit, there
were no significant differences during the visits at the
three different times (p > 0.05).
MUC5B. The results showed a trend of increased
MUC5B salivary concentration; however, a slight
decrease was noted at the sixth visit (Table 2). There
was no significant difference between the first and sixth
visits (p = 0.875). In contrast, significant increases were
found between the first visit and the 6-week follow-up
visit (p = 0.037) and between the sixth visit and the 6week follow up visit (p = 0.028).
Histatin 5. Although the sixth visit showed slightly
increased histatin 5 salivary concentrations, the overall
trend demonstrated decreased histatin 5 concentration
(Table 2). Histatin 5 concentrations did not significantly
differ between the first and sixth visits (p = 0.530).
Nonetheless, significant decreases were found between
the first visit and the 6-week follow up visit (p = 0.047)
and between the sixth visit and the 6-week follow up
visit (p = 0.022).
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Table 2. Mean Salivary Flow Rates, Salivary Protein Concentrations and Dry Mouth Scores

USFR
(mL/min ± SD)
SSFR
(mL/min ± SD)
MUC7
(ng/mL ± SD)
MUC5B
(ng/mL ± SD)
Histatin 5
(ng/mL ± SD)
Dry mouth score
(x̅ ± SD)
#

First visit#

End of therapy##

6-week
follow-up visit

p*

0.14 ± 0.08a,b

0.29 ± 0.16a

0.32 ± 0.16b

<0.01

0.79 ± 0.47

0.92 ± 0.43

0.94 ± 0.42

0.232

3.29 ± 5.36

2.49 ± 4.05

2.43 ± 5.04

0.519

9.15 ± 5.15a

8.08 ± 2.92b

13.78 ± 8.65a,b

<0.05

192.10 ± 141.52a

234.86 ± 245.98b

100.89 ± 8.65a,b

<0.05

4.05 ± 3.25a,b

1.26 ± 1.18a

1.03 ± 1.19b

<0.001

##

Baseline, End of therapy
*Friedman test
a,b
Groups with the same superscript letters are significantly different according to the Wilcoxon signed-rank test.

Table 3. Mean Dry Mouth Scores of Each Questionnaire Item per Visit
V1
(mean ± SD)
2.42 ± 2.87
3.08 ± 3.53
3.83 ± 3.27a
4.75 ± 2.89a,b
2.42 ± 2.87
2.67 ± 2.96
5.67 ± 3.14a,b
3.92 ± 3.50a,b
4.5 ± 3.87a
4.00 ± 3.69
2.17 ± 2.17

Questionnaire Items
SIP-LIQ
DRY-MEL
NGT-DRK
MTH-DRY
DIF-DRY
SWT-DRY
LIP-DRY
DEN-CAR
BAD-BRH
TNG-PLT
BLD-BRS

V2
(mean ± SD)
0.92 ± 0.99
1.50 ± 0.79
0.92 ± 0.79a
1.50 ±1a,c
1.33 ± 0.98
1.08 ± 1.38
1.17 ± 0.83a
1.75 ± 1.91a
1.58 ± 1.62a
1.00 ± 0.74
0.83 ± 0.94

V3
(mean ± SD)
0.90 ± 0.99
1.10 ± 0.99
1.33 ± 1.06
0.80 ± 0.63b,c
1.20 ± 1.13
0.60 ± 0.84
1.60 ± 1.50b
1.40 ± 1.78b
1.70 ± 1.83
0.70 ± 0.67
1.20 ± 1.39

p*
0.291
0.483
0.042
0.002
0.965
0.070
0.001
0.042
0.016
0.072
0.28

V1: Baseline; V2: End of therapy; V3: 6-week follow-up visit
*Friedman test
a,b,c
Groups with the same superscript letters are significantly different according to the Wilcoxon signed-rank test.

Table 4. Correlation between Mean the Dry Mouth Score and Salivary Flow Rate during the Different Visits
USFR
##

Sixth visit
Mean dry mouth
score*

0.549
(p = 0.064)

SSFR
6-week
follow-up visit
0.102
(p = 0.778)

##

Sixth visit

0.387
(p = 0.215)

6-week
follow-up visit
0.121
(p = 0.740)

##

End of therapy
*Based on questionnaire items 4 and 7

Dry Mouth Score. The mean dry mouth scores
demonstrated a decreasing trend over the course of the
study (Table 2). Significant decreases in the mean dry
Makara J. Health Res.

mouth score were found between the first and sixth
visits (p < 0.001) and between the first visit and the 6week follow-up visit (p < 0.001) Although a slight
April 2018 | Vol. 22 | No. 1
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decrease was observed between the sixth visit and the 6week follow-up visit, the difference was not significant
(p = 0.268).
The mean dry mouth scores for each questionnaire item
are seen in Table 3. Item 7 (my lips feel dry) had the
highest mean score (5.67 ± 3.14) at the first visit,
followed by item 4 (my mouth feels dry) (4.75 ± 2.89)
and item 9 (4.5 ± 3.87) (I have bad breath). Items 4, 7, 3
(I get up at night to drink), 8 (I have a lot of dental
caries) and 9 showed significant decreases from the first
visit to the 6-week follow-up visit (p < 0.05 for items 3,
8 and 9 and p < 0.01 for items 4 and 7) (Table 3).
However, only item 4 exhibited a significant timedependent decrease. Only items 4 and 7 were used in
the correlation analysis at the sixth visit and 6-week
follow-up visit because they best represent dry mouth.
The results revealed no significant differences between
mean dry mouth scores and salivary flow rates at the
sixth visit and 6-week follow-up visit (Table 4).
However, the strongest positive correlation between
these parameters was found at the sixth visit (rs = 0.549).

Discussion
The present study evaluated the effect of LLLT on
major salivary gland function in diabetic patients with
hyposalivation. Our findings showed that LLLT to the
major salivary glands significantly increased the USFR
and MUC5B salivary concentration and alleviated
patients’ dry mouth symptoms.
We found that LLLT increased the USFR in diabetic
patients; however, the elevation in SSFR was not
significant. The normal USFR is at least 0.25 mL/min,2
and the mean USFR of 0.14 mL/min found at the first
visit was below this value. After LLLT, the mean
USFR, but not the SSFR, increased to within the normal
range. Our results are consistent with those of a
previous study on subjects with hyposalivation.21-23
These findings may result from LLLT inducing ATP
production by activating the electron transport chain in
mitochondria,24 stimulating cell function. However.
LLLT did not improve either the USFR or xerostomia in
patients undergoing radiotherapy;25 this may be due to
acinar atrophy and chronic salivary gland inflammation,
which may lead to necrosis,26 implying that LLLT is not
effective on atrophic glands and suggesting that the
response of the major salivary glands to LLLT differs
under physiological and pathological conditions.
The typical MUC5B concentration in unstimulated whole
saliva ranges from 0.05 ng/mL to 0.78 ng/mL.27 Surprisingly, our patients showed much higher concentrations
of both mucins compared with the normal values, which
could possibly be explained by the difference in salivary
protein content in diabetics compared with non-diabetics.
Increased MUC1 concentrations in saliva are associated
Makara J. Health Res.

with the presence of proinflammatory cytokines.28 Diabetes
is an inflammatory disease; thus, the higher mucin
concentration found in our study is likely due to changes
in proinflammatory cytokine levels in the salivary
glands of diabetic patients.29 LLLT-induced significant
increase in MUC5B concentrations found at the 6-week
follow-up visit may have resulted from the biomodulatory effect of LLLT on the major salivary glands.
We observed a lower concentration of MUC7 than of
MUC5B, which is consistent with a previous report
demonstrating that MUC5B is the predominant mucin in
saliva.30 Our results showed that the MUC7 concentration
was higher than normal (3.29 ± 5.36 ng/mL vs 0.06–
0.32 ng/mL)27 and did not significantly increase by
LLLT. MUC7, but not MUC5B, is localised in serous
acini in the sublingual, submandibular, lingual and
palatine glands.31 The slight decrease in MUC7
concentration in our study may be due to damaged
serous acini in diabetic patients.
A previous study revealed lower salivary histatin
concentrations in diabetic children than in controls,32
suggesting that the antifungal and bacterial enzyme
inhibition activities of histatin may not be optimal in
diabetic patients. However, further investigations are
necessary to resolve these issues. We found that the
salivary histatin 5 concentration significantly decreased
at the 6-week follow-up visit, which does not agree with
the result of a previous investigation demonstrating that
LLLT had a mild disinfecting effect against C. albicans
and reduced inflammation in denture stomatitis
patients.33 Previous studies concluded that serous cells
in the parotid glands of diabetic patients are prone to
intracellular lipid accumulation,29,31,32,34 this may explain
the decreased histatin 5 concentrations found in our
study because serous cells in the parotid glands are
involved in secreting this protein.9 Moreover, dissimilar
levels of diabetes severity among the patients in our
study may have resulted in different acinar cell function
between them as most diabetic patients take multiple
drugs, whose use is related to salivary gland
hypofunction.2 The decreased histatin 5 concentration at
the follow-up visit supports the insignificant increase in
the SSFR found in our study, suggesting that the parotid
glands of diabetic patients are more sensitive to salivary
gland impairment, given that the parotid glands
contribute to stimulated salivary secretion and histatin 5
production.
As indicated by the dry mouth score results, LLLT
decreased the subjective dry mouth symptoms
throughout the course of our study, which is in line with
previous reports that found that LLLT effectively
reduced dry mouth symptoms.12,14,15,34 Among all
questionnaire items, item 4 (my mouth feels dry)
demonstrated the highest mean score prior to LLLT,
indicating that the major subjective sign of dry mouth is
April 2018 | Vol. 22 | No. 1
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the feeling of dryness inside the mouth, as found in a
previous study.22
The questionnaire analysis revealed that items 4 (my
mouth feels dry) and 7 (my lips feel dry) significantly
decreased following LLLT, indicating that laser therapy
reduces diabetes-induced dry mouth symptoms. A
previous study also found an association between
diabetes and dry mouth symptoms.35 It is important to
note that item 4 significantly decreased at each visit,
indicating that LLLT alleviated most dominant dry
mouth symptoms in the present study.
The strongest positive correlation between mean the dry
mouth score and the salivary flow rate was seen at the
sixth visit, implying that the maximum reduction in dry
mouth symptoms was achieved after the sixth laser
exposure; however, no significant differences were found
among the visits. These results are similar to those of a
previous study,25 which concluded that decreased dry
mouth symptoms are not always directly proportional to
increased salivary flow rates and vice versa.
One aspect concerning our statistical analysis is that the
SPSS Friedman test was unable to assess unequal
patient numbers in the three visits due to two patients
not attending the 6-week follow-up visit. To resolve this
issue, the test was performed using 10 patients, excluding
the data from the missing patients. However, the mean
scores presented in this study represent the values from
all 12 patients, except for the 6-week follow up data that
were based on the 10 patients who attended the followup visit.

achieve optimal results in diabetic patients. The slight
decrease in MUC7 concentrations observed in our study
may be a result of damage to the sublingual, submandibular, lingual and palatine gland serous cells in the
diabetic patients. Applying laser therapy over the minor
glands as well as the major salivary glands may result in
even higher increases in salivary flow and quality; this
should be explored in future studies. To the best of our
knowledge, our report is the first to use LLLT on the
salivary glands in diabetic patients. However, we only
evaluated a few diabetic patients due to the limited
study duration and difficulty in recruiting patients.

Conclusions
LLLT is a beneficial approach to elevate the USFR and
MUC5B concentration and to decrease dry mouth
symptoms in diabetic patients with hyposalivation.
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The laser parameters used in our study were 0.1 W
power and 4 J/cm2 ED, which has been suggested as the
most effective ED for cell stimulation.12,14,15,19,20 In
addition, our pilot study using five study patients found
that their salivary flow rates increased; thus, these
parameters were used throughout the present study.
Moreover, previous experimental models have demonstrated that LLL at therapeutic intensities penetrated
living tissue from 2 cm to 5 cm, including the scalp and
bone and reaching the bone tissue, depending on the
types of tissue layers involved and the patient’s
metabolic status.36-45 Although there may be a reduction
in laser light energy due to tissue absorption, reflection
or refraction, it is reasonable to assume that LLLT
reached the major salivary glands, including both lobes
of the parotid gland. Additional investigations are
necessary to determine the optimum therapeutic level
using a range of energy levels.

3.

Our study showed that the LLLT-induced increase in
the SSFR was not significant and that histatin 5
concentration decreased. Because the parotid glands are
responsible for the SSFR and histatin 5 secretion, it may
be necessary to use a higher laser ED on these glands to

7.
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